Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Total studies: 9 Total participants: 1757
1 finding from 1 review
no estimate extracted
9 participants
GRADE not reported
Dactolisib (1 RCT; 62 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes dactolisib (1 RCT; 62 participants) compared with placebo (very low certainty).
2 findings from 1 review
Total studies: 10 Total participants: 2113
1 finding from 1 review
no estimate extracted
10 participants
GRADE not reported
Everolimus
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower everolimus (3 RCT; 632 participants) compared with placebo (moderate certainty).
4 findings from 1 review
HR 0.36 [0.28, 0.46]
3 studies · 632 participants
Moderate
OR 3.29 [2.21, 4.9]
3 studies · 632 participants
Moderate
OR 2.53 [0.95, 6.79]
1 study · 302 participants
Very low
Show 1 more finding
Interferon + SSA (2 RCTs; 171 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon + SSA (2 RCTs; 468 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.34 [0.14, 0.8]
2 studies · 468 participants
Very low
OR 5.71 [1.9, 17.2]
4 studies · 283 participants
Very low
HR 0.23 [0.06, 0.93]
3 studies · 512 participants
Very low
Show 1 more finding
Everolimus + SSA (1 RCT; 39 participants)
Estimates of effects, ranking, and certainty of evidence for… may leads to lower everolimus + SSA (3 RCTs; 739 participants) compared with placebo (low certainty).
4 findings from 1 review
HR 0.38 [0.26, 0.57]
3 studies · 739 participants
Low
OR 15.1 [2.55, 88.9]
1 study · 39 participants
Very low
OR 2.89 [1.61, 5.19]
2 studies · 589 participants
Moderate
Show 1 more finding